Nike Inc
Change company Symbol lookup
Select an option...
NKE Nike Inc
AAPL Apple Inc
VXRT Vaxart Inc
VIGI Vanguard International Dividend Appreciation Index Fund ETF Shares
VIG Vanguard Dividend Appreciation Index Fund ETF Shares
VIAC ViacomCBS Inc
VGK Vanguard FTSE Europe Index Fund ETF Shares
VGI Virtus Global Multi-Sector Income Fund
VDE Vanguard Energy Index Fund ETF Shares
VCV Invesco California Value Municipal Income Trust

Consumer Discretionary : Textiles, Apparel & Luxury Goods | Large Cap Blend
Company profile

NIKE, Inc. is engaged in the design, development, marketing and selling of athletic footwear, apparel, equipment, accessories and services. The Company's operating segments include North America, Western Europe, Central & Eastern Europe, Greater China, Japan and Emerging Markets. Its portfolio brands include the NIKE Brand, Jordan Brand, Hurley and Converse. As of May 31, 2016, the Company focused its NIKE brand product offerings in nine categories: Running, NIKE Basketball, the Jordan Brand, Football (Soccer), Men's Training, Women's Training, Action Sports, Sportswear (its sports-inspired lifestyle products) and Golf. Men's Training includes its baseball and American football product offerings. It also markets products designed for kids, as well as for other athletic and recreational uses, such as cricket, lacrosse, tennis, volleyball, wrestling, walking and outdoor activities. The Company sells a range of performance equipment and accessories under the NIKE Brand name.


Last Trade
0.88 (0.84%)
B/A Size

Market Hours

Closing Price
Day's Change
0.00 (0.00%)
B/A Size
Day's High
Day's Low

10-day average volume:

Aurora Cannabis downgraded by Jefferies as re-rating 'neither justified nor sustainable'

6:53 am ET May 22, 2020 (MarketWatch)

Jefferies downgraded Aurora Cannabis Inc. stock (ACB.T) on Friday to underperform from hold and said the recent re-rating following better-than-expected earnings was neither justified nor sustainable. Aurora shares have gained 110% in the month to date, after rallying hard following last week's earnings report ( "We think near-term sales and GM (gross margin) headwinds are not fully appreciated, while celebrating a hiatus on further dilution is short-sighted, it (is) inevitably returning again when the balance sheet is addressed," analyst Owen Bennett wrote in a note to clients. "Still set-up well longer-term but we see give back in the price over the next few quarters as likely." The analyst raised his stock price target to C$14 ($9.99) from C$12, to include estimates for Reliva, the U.S. CBD company that Aurora has acquired this week in an all-stock transaction ( "Aurora's ex-COO once described US entry as non-negotiable. We agree, though we do view this particular deal/timing as strange," Bennett wrote. "There is still no permanent CEO to lead this CBD push, the CBD space is experiencing significant headwinds currently, there is further dilution at a questionable multiple which has been a criticism of the past, and the B/S (balance sheet) does not afford investment behind the purchase." Aurora's U.S.-listed shares were down 4% premarket and are down 33% in the year to date, while the Cannabis ETF (THCX) has fallen 18% and the S&P 500 has fallen 9%.

-Ciara Linnane; 415-439-6400;

(END) Dow Jones Newswires

May 22, 2020 06:53 ET (10:53 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.